Regeneron Pharmaceuticals announced Monday that a Phase 3 trial of its antibody cocktail offered strong protection against COVID-19 for people living with someone infected with the coronavirus.
The treatment lessens the likelihood of infection and improves outcomes for those who do become infected, Regeneron said in a statement. The treatment also appears to be potent against emerging variants, the company said.
The data suggests the treatment “can complement widespread vaccination strategies, particularly for those at high risk of infection,” said Myron Cohen, M.D., who leads the monoclonal antibody efforts for the NIH-sponsored COVID Prevention Network.
Regeneron’s cocktail, a combination of two drugs, was given to former President Donald Trump when he became ill with the virus. The company said it will share data with the FDA and request emergency use authorization expansion to include COVID prevention for appropriate populations.
Also in the news:
►Illinois opened up vaccine eligibility to those 16 and older Monday, and on Thursday Washington state and California will join the more than 40 states providing vaccine access to all adults.
►For the first time in months, shops, hairdressers and pub “gardens” reopened Monday in England. British Prime Minister Boris Johnson has urged people to “behave responsibly.” Northern Ireland’s “stay-at-home” order is ending and some rules are being relaxed in Scotland and Wales.
►Travel is rising throughout the…
